Preferential potentiation by nitric oxide of spontaneous inhibitory postsynaptic currents in rat supraoptic neurones. 2000

M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
Department of Physiology, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.

Magnocellular neurones in the supraoptic nucleus and paraventricular nucleus express mRNA for nitric oxide synthase (NOS) and the expression becomes more prominent when the release of vasopressin or oxytocin is stimulated. It has also been reported that NO donors inhibit the electrical activity of supraoptic nucleus neurones, but the mechanism involved in the inhibition remains unclear. In the present study, to know whether modulation of synaptic inputs into supraoptic neurones is involved in the inhibitory effect of NO, we measured spontaneous excitatory and inhibitory postsynaptic currents (EPSCs and IPSCs) from rat supraoptic nucleus neurones in slice preparations identified under a microscope using the whole-cell mode of the slice-patch-clamp technique. The NO donor, S-nitroso-N-acetylpenicillamine (SNAP), reversibly increased the frequency of spontaneous IPSCs mediated by GABAA receptors, without affecting the amplitude, indicating that NO potentiated IPSCs via a presynaptic mechanism. The NO scavenger, haemoglobin, suppressed the potentiation of IPSCs by SNAP. On the other hand, SNAP did not cause significant effects on EPSCs mediated by non-NMDA glutamate receptors. The membrane permeable analogue of cGMP, 8-bromo cGMP, caused a significant reduction in the frequency and amplitude of both IPSCs and EPSCs. The results suggest that NO preferentially potentiates the inhibitory synaptic inputs into supraoptic nucleus neurones by acting on GABA terminals in the supraoptic nucleus, possibly via a cGMP-independent mechanism. The potentiation may, at least in part, account for the inhibitory action of NO on the neural activity of supraoptic neurones.

UI MeSH Term Description Entries
D008297 Male Males
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004553 Electric Conductivity The ability of a substrate to allow the passage of ELECTRONS. Electrical Conductivity,Conductivity, Electric,Conductivity, Electrical
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013495 Supraoptic Nucleus Hypothalamic nucleus overlying the beginning of the OPTIC TRACT. Accessory Supraoptic Group,Nucleus Supraopticus,Supraoptic Nucleus of Hypothalamus,Accessory Supraoptic Groups,Group, Accessory Supraoptic,Groups, Accessory Supraoptic,Hypothalamus Supraoptic Nucleus,Nucleus, Supraoptic,Supraoptic Group, Accessory,Supraoptic Groups, Accessory,Supraopticus, Nucleus

Related Publications

M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
November 2004, Journal of neuroendocrinology,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
November 1999, Journal of neuroendocrinology,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
March 2009, Brain research,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
October 1998, Brain research,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
November 2009, Journal of neuroendocrinology,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
September 1988, The Journal of physiology,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
October 2001, Neuropharmacology,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
September 1990, The Journal of physiology,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
January 2010, Neuroscience,
M Ozaki, and I Shibuya, and N Kabashima, and T Isse, and J Noguchi, and Y Ueta, and Y Inoue, and A Shigematsu, and H Yamashita
September 1996, The Journal of physiology,
Copied contents to your clipboard!